MSD
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
InflaRx reports positive phase 2 results for HS and CSU treatments
Topline results demonstrated treatment efficacy for both conditions
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer
More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK
Merck unveils $3bn cost-cutting plan to support pipeline and new product launches
A new restructuring programme has been approved to support the initiative
MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive
Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Cardiovascular diseases result in an estimated 17.9 million global deaths each year
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults
The inflammatory skin disease affects approximately one in every 100 people in the US
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
The inflammatory skin disease affects about 1% of the population in most studied countries
MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease
Approximately one in every 70,000 people are affected by the tumour-causing genetic disease
Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa
Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition